- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04088019
Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive
Proportion of Clinical Improvement and Score Comparison of Type 1 Interferon, Transcriptomic Analysis in Idiopathic Uveitis Patients With IGRA Positive Before and After Anti-Tuberculosis Drugs Treatment: Cohort Prospective Study
The aim of this study is to determine the proportion of clinical improvement, the score changing of type 1 interferon selected gene expression, and analysis of transcriptomics profiling in patients with idiopathic uveitis positive IGRA before and after receiving Anti-Tuberculosis Therapy (ATT).
Hopefully, by conducting this research, we are able to provide valid data that demonstrate the advantages/disadvantages usage of Anti-Tuberculosis Therapy in patients with idiopathic uveitis IGRA positive that correlate with type I IFN. This research is a part of our efforts in discovering bio-marker candidates of idiopathic uveitis IGRA positive clinical patients who will benefit from the ATT administration.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Rina La Distia Nora
- Phone Number: +62811-198-910
- Email: rina.ladistia@ui.ac.id
Study Locations
-
-
Jakarta
-
Jakarta Pusat, Jakarta, Indonesia, 10430
- Recruiting
- RSUPN dr. Cipto Mangunkusumo (Cipto Mangunkusumo Hospital)
-
Contact:
- Rina La Distia Nora
- Phone Number: +62811198910
- Email: rina.ladistia@ui.ac.id
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria:
Subjects who will be recruited to this study are patients who met the criteria described below:
- Registered patients from September 2019 at Cipto Mangunkusumo Hospital
- Idiopathic uveitis patients (proven having negative result by available etiological uveitis work-ups) with IGRA positive. IGRA positive value is defined by score above 0.35 u/ml obtained from Quantiferon Tuberculosis (QFT)-Gold Assay (QIAGEN).
- Minimum age: 18 years old
- Proven not having active Tuberculosis
- Not previously received Anti Tuberculosis Therapy.
- Not consuming antibiotic one to two weeks prior to the time of study
- Not living together with Tuberculosis active patient
- Not having plan to become pregnant during the time of study
- Not part of reactive Tuberculosis risk group based on Latent Tuberculosis Incident WHO guidelines 2018
Active inflammation in the past 180 days characterized by the following sign based on SUN Criteria(in at least one eye)
- ≥ 2+ anterior chamber cells
- ≥ 2+ vitreous haze
- active retinal or choroidal lesions
Active inflammation during patient registration, characterized by the following sign based on SUN Criteria (in at least one eye)
- ≥1+ anterior chamber cells and/or
- ≥1+ vitreous haze and/or
- active retinal/choroidal lesions
Exclusion Criteria:
- Not willing to sign informed consent
- Pregnant patient
- Not coming to scheduled visit date
- Uveitis caused by infectious origin
- Media opacity caused by cataract and/ or corneal scar resulting in difficulty of posterior segment examination in both eyes
- Chronic hypotony (IOP < 5 mm Hg for > 3 months) in both eyes
- History of prior intraocular surgery in < 30 days, or arranged surgery within the next 6 months
- Best spectacle-corrected visual acuity (BSCVA) of hand motions or worse in better eye
- Any history of cancer excluding non-melanoma skin cancer
- Abnormal Complete blood count (≤ 2,500 white blood cells and/or ≤ 75,000 platelets and/or ≤9 hemoglobin) within 4 weeks prior to enrollment^
- Abnormal alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 2 times the upper limit of normal for the lab and/or creatinine ≥ 1.5 within 4 weeks prior to enrollment^
- Patient with active infection of tuberculosis, HIV infection, syphilis, or hepatitis B or C
Note (^): Testing is conducted within 1-2 weeks prior to enrollment;
As many 10 subjects of the health volunteers are recruited for this study after giving consent. The health volunteers that will be recruited are the subject who met following criteria:
- age: 18-50 years old (Man/Woman)
- not having any health complaint or symptoms
- not in any long term medication
- body mass index: 18.5 - < 30
- no history of allergy
- willing to cooperate in this study
- state of complete physical, mental, and social well being, and not merely the absence of disease or infirmity (WHO healthy definition)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational cohort group
Subjects: idiopathic uveitis with IGRA positive. Examinations:
|
In the first two week, patients receive FDC of ATT only. Oral steroid start to be given in week three. The ATT regiment is continued for up to 6 months or more, in accordance with WHO guidelines. In the first two months the antibiotic combination given consisted of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. The next four months or continuation phases, the ATT given is rifampicin and isoniazid. The following dosage and administration of oral steroids will be given to patients, according to guidelines from the American Journal of Ophthalmologists (Douglas A. Jabs et al, 2000): Initial dose: 1mg/kg/day, with maximum adult oral dose 60-80 mg/kg and maintenance dose less than or equal to 10 mg/day. The tapering schedule: Over 40 mg/day, decrease by 10 mg/day every 1-2 weeks, 40-20 mg/day, decrease by 5 mg/day every 1-2 weeks, 20-10 mg/day, decrease by 2.5 mg/day every 1-2 weeks, 10-0 mg/day, decrease by 1 to 2.5 mg/day every 1-4 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of clinical improvement
Time Frame: 0, 14 days, 8 weeks, 3 months, 6 months, and 12 months
|
Clinical improvement of uveitis patients with IGRA positive after receiving complete Anti Tuberculosis Therapy is measured by using The Standardization of Uveitis Nomenclature (SUN) inflammation degree.
Clinical improvement definition is decreasing of inflammation degree up to two degrees or becoming 0 degree.
Meanwhile, clinical failure is defined by increasing of inflammation degree or decreasing of inflammation degree up to one degree/ not becoming 0 degree or unchanged degree of first to fourth degree.
|
0, 14 days, 8 weeks, 3 months, 6 months, and 12 months
|
The changes of type 1 interferon scoring in selected gene expression
Time Frame: 0, 14 days, 6 months.
|
The score changes of type 1 interferon of uveitis patients with IGRA positive are determined by gene expression value of 10 varieties of type 1 interferon using Quantitative Reverse Transcriptase PCR (RT-qPCR) testing.
|
0, 14 days, 6 months.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rina La Distia Nora, Division of Ophthalmology Departement, Faculty of Medicine Universitas Indonesia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-06-0769
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anti-Tuberculous Drug Reaction
-
Sun Yat-sen UniversityUnknownNon-steroidal Anti-inflammatory Drug Adverse ReactionChina
-
University of EdinburghNHS LothianUnknownTuberculosis | Drug-Induced Liver Injury | Anti-Tuberculous Drug ReactionUnited Kingdom
-
Chiang Mai UniversityCompletedAnti-Infectives Adverse ReactionThailand
-
Assiut UniversityNot yet recruitingAntiarrhythmic Drug Adverse Reaction
-
Population CouncilCompleted
-
Romanian Society of Anesthesia and Intensive CareUnknownGeneral Anesthetic Drug Adverse ReactionRomania
-
University Hospital Hradec KraloveCompletedGeneral Anesthetic Drug Adverse ReactionCzech Republic
-
University Hospital, GrenobleTerminatedAllergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross ReactionFrance
-
CHU de ReimsActive, not recruitingAutoimmune Adverse Effects of Anti-neoplasic DrugFrance
-
Damanhour Teaching HospitalRecruitingGeneral Anesthetic Drug Adverse ReactionEgypt
Clinical Trials on Fixed drug combination (FDC) of ATT and Oral steroid
-
Janssen-Cilag S.p.A.CompletedHuman Immunodeficiency Virus (HIV)Italy
-
NewAmsterdam PharmaActive, not recruitingHealthy Volunteer StudyUnited States
-
Michael SavonaIncyte Corporation; Astex Pharmaceuticals, Inc.; TheradexRecruiting
-
Duke UniversityGilead SciencesCompletedHeart Failure | Pulmonary Disease, Chronic Obstructive | Hepatitis C, Chronic | Lung Diseases, InterstitialUnited States
-
Almirall, S.A.proDERM GmbHCompleted
-
Rockefeller UniversityNational Institute on Drug Abuse (NIDA)Completed
-
University Hospital, Clermont-FerrandMerck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Bristol-Myers SquibbCompleted
-
Melanoma Institute AustraliaBristol-Myers SquibbRecruiting